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Background and aims: Dysregulated lipid metabolism has emerged as one of the major risk 2 
factors of atherosclerosis. Presently, there is a consensus that oxidized LDL (oxLDL) promotes 3 
development of atherosclerosis and downstream chronic inflammatory responses. Due to the 4 
dynamic metabolic disposition of lipoprotein, conventional approach to purify bioactive lipids 5 
for subsequent comprehensive analysis has proven to be inadequate for elucidation of the 6 
oxidized lipids species accountable for pathophysiology of atherosclerotic lesions. Herein, we 7 
aimed to utilize a novel mass microscopic imaging technology, coupled with mass 8 
spectrometry (MS) to characterize oxidized lipids in atherosclerotic lesions.  9 
Methods: We attempted to use MALDI-TOF-MS and iMScope to identify selected oxidized 10 
lipid targets and visualize their respective localizations in study models of atherosclerosis.  11 
Results: Based on the MS analysis, detection of 7-K under positive ionization through product 12 
ion peak at m/z 383 [M+H-H2O] indicated the distinctive presence of targeted lipid within Cu
2+-13 
oxLDL and Cu2+-oxLDL loaded macrophage-like J774A.1 cell, along with other cholesterol 14 
oxidation products. Moreover, the application of two-dimensional iMScope has successfully 15 
visualized the localization of lipids in aortic atherosclerotic plaques of the Watanabe heritable 16 
hyperlipidemic (WHHL) rabbit. Distinctive lipid distribution profiles were observed in 17 
atherosclerotic lesions of different sizes, especially the localizations of lysoPCs in 18 
atherosclerotic plaques.  19 
Conclusions: Taken together, we believe that both MALDI-TOF-MS and iMScope 20 
metabolomics technology may offer a novel proposition for future pathophysiological studies 21 
of lipid metabolism in atherosclerosis. 22 
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Metabolic abnormalities of lipoproteins have an intimate involvement in the pathogenicity 2 
of lifestyle diseases, such as cardiovascular diseases and diabetes mellitus [1]. Low-density 3 
lipoprotein (LDL), that contains cholesterol and cholesteryl esters (CEs) at nearly 50 % of its 4 
composition, is most susceptible to oxidative damage than other lipoproteins. The oxidation of 5 
native LDL (nLDL) into oxidized LDL (oxLDL) is generated by reactive oxygen species 6 
(ROS), such as superoxide anions or hydroxyl radicals in the blood vessels [2]. 7 
The lipid components of an oxLDL particle generally include CEs, sterols, oxysterols 8 
(oxygenated derivatives of cholesterol), phospholipids, lysophosphatidylcholine (lyso-PC), 9-9 
hydroxyoctadecadienoate (9-HODE), 13-hydroxyoctadecadienoate (13-HODE), hydroxyl 10 
fatty acids, etc. [3, 4]. Among all, oxysterols are allegedly the most toxic components of oxLDL 11 
[5, 6]. They exist in human atherosclerotic plaques and actively involved in plaque 12 
development [7, 8]. 7-ketocholesterol (7-K), coming in second after 27-hydroxycholesterol 13 
(27-OH), is one of the most abundant forms of oxysterol detected in human atherosclerotic 14 
plaques. It is formed non-enzymatically from the intermediate by-product of cholesterol 15 
oxidation, 7-hydroperoxycholesterol (7-OOH), and it carries a ketone functional group. The 16 
involvement of 7-K in manifestation of atherosclerosis has been apparent. It emerged as a 17 
potent apoptotic inducer to which the embodiment of 7-K to lipid raft domains of plasma 18 
membranes has been reported to propagate apoptotic signals [9, 10]. 19 
In plasma, the majority of the cholesterols and their oxidized forms, oxysterols, exist in 20 
esterified forms. Approximately 75% of the linoleic acid in LDL exists in esterified form, as a 21 
CE of linoleic acid (CE 18:2) [11, 12]. The CE 18:2 is subsequently converted to hydroxy-22 
octadecadienoate-CE (HODE-CE) following the reduction of its initial hydroperoxide product, 23 
the hydroperoxy-octadecadieoate-CE (HpODE-CE) [12, 13], the oxo-octadecadienoate-CE 24 



































































aldehydes” [14-16]. These severely oxidized CE (oxCE) were detected and have been shown 1 
to accumulate in human atheroma and human plasma [15, 17, 18]. In Cu2+-oxidized LDL, 9-2 
oxononanoylcholesterol (9-ONC) exists as a major form of oxCE [19] and subsequent 3 
oxidation of its cholesterol backbone resulted in formation of 7-ketocholesteryl-9-4 
carboxynonanoate (oxLig-1). Our previous studies have reported that the oxCE-based oxidant 5 
associated with the onset of autoimmunity and atherosclerosis was identified as oxLig-1 and 6 
its downstream signaling pathways involving CD36 were reported [20-22]. 7 
β2-glycoprotein I (β2GPI) is a glycoprotein that is known to bind specifically to 8 
hydrophobic anionic moieties such as oxLDL and has been shown to dose-dependently inhibit 9 
the scavenger receptor-mediated uptake of oxLDL by macrophages [23]. In addition, 10 
immunization of Ldlr knockout (Ldlr-/-) mice with β2GPI was reported to promote formation 11 
of atherosclerotic plaque with extensive localization of glycoprotein at the plaque legions [24]. 12 
Our previous studies reported that β2GPI binds electrostatically to oxLDL and form 13 
oxLDL/β2GPI complexes through specific ligands, known as oxLig-1. OxLig-1 is structurally 14 
consisting of 7-K and an acyl chain with a terminal carboxyl group (Supplementary Fig. 1). 15 
 Our previous studies have substantiated the functions of these oxLDL/β2GPI complexes 16 
as major atherogenic and thrombogenic autoantigens in patients with the antiphospholipid 17 
syndrome. These complexes were also detected in patients with diabetes mellitus and chronic 18 
renal diseases [23, 25-28]. In addition, we have demonstrated that the uptake of oxLDL/β2GPI 19 
complexes by macrophages (through its Fc receptors) was significantly enhanced in the  20 
presence of anti-oxLDL/β2GPI IgG autoantibodies and has notably accelerated the formation 21 
of foam cells and progression of atherosclerosis [27, 29-32].  22 
Inflammation plays a key role in physiological oxidation and degeneration of lipoproteins. 23 
The constant shifting of lipoprotein particle size and its dynamic metabolic disposition have 24 



































































comprehensive analysis. As such, the novel method of utilizing imaging mass microscope 1 
(iMScope) system with MS/MS imaging for direct detection and identification of bioactive 2 
lipids is deem pivotal to elucidate the pathology of atherosclerosis. iMScope is a novel imaging 3 
mass spectrometry, composed of an optical microscope and a hybrid ion trap time of flight 4 
mass spectrometer. The system has a resolution of 5 m and capable of visualizing the 5 
distribution of molecules at sub-cellular level. Herein, our present work focused on the 6 
establishment of novel iMScope and MS/MS imaging metabolomic technology to characterize 7 
different oxidized lipids in atherosclerotic lesions. The distributions of oxidized lipids in the 8 
aortic lesions were thoroughly visualized with iMScope and elucidated by MS/MS imaging 9 
technology. Such novel approach may offer new method to comprehensively unravel the 10 



































































Materials and methods 1 
Chemicals and reagents 2 
Mass spectrometry grade chemicals and reagents were used in the present study. 2, 5-3 
dihydroxybenzoic acid (DHB) was purchased from Shimadzu GLC Ltd (Kyoto, Japan). 4 
Lipid moieties inclusive of 27-hydroxycholesterol (27-OH), 25-hydroxycholesterol (25-5 
OH), 7-ketocholesterol (7K), N-palmitoyl-D-erythro-sphingosylphosphorylcholine 6 
[SM34:1, (d18:1/16:0)], phosphatidylcholine 16:0/16:0 (DPPC) and phosphatidylcholine 7 
(PC) 16:0/18:2 were purchased from Avanti Polar Lipids Inc. (Alabaster, AL). 8 
Cholesterol, 7β-Hydroxycholesterol (7β-OH) and cholesteryl linoleate (CE 18:2) were 9 
obtained from Sigma-Aldrich Japan G.K. (Tokyo, Japan). 9(R)-HODE cholesteryl ester or 10 
(±) 13-HODE cholesteryl ester (HODE-CE), and cholesteryl linoleate hydroperoxides 11 
(oxo-octadecadienoate-CE, oxoODE-CE) were purchased from Cayman Chemical 12 
Company (Ann Arbor, MI). OxLig-1 was synthesized in-house as described previously 13 
[20] and the structure was verified by MALDI-TOF-MS/MS analysis. 14 
Animal Studies 15 
The study was adhered to the Ethical Committee’s Guidelines for Animal Research at 16 
Okayama University. Twelve atherosclerosis-prone mouse strains, Ldlr-/- mice, with a 17 
C57BL/6 genetic background (Jackson Laboratories, Bar Harbor, ME) were used and their 18 
genotypes were verified via polymerase chain reaction (PCR). After 8 weeks of age, mice 19 
were fed with high-fat diet (containing cholic acid) for 8 weeks. Mice were then sacrificed 20 
to harvest the whole blood for isolation of LDL. One Watanabe heritable hyperlipidemic 21 
(WHHL) rabbit (Brown Family Enterprises, LLC., Odenville, AL) was fed with the regular 22 
rabbit diet for 6 months and sacrificed to harvest the thoracic aorta. The collected specimen 23 



































































Isolation and oxidation of LDL 1 
The LDL fraction was collected from fresh plasma of high-fat diet-fed Ldlr-/- mice (16 2 
weeks old, n=12) by ultracentrifugation, as described previously [33]. LDL was then oxidized 3 
with 5 μM of CuSO4 for 16 hours at 37 °C. Oxidation was terminated by addition of EDTA to 4 
the reaction mixture (at a final concentration of 1 mM). The oxidized LDL fraction was 5 
dialyzed against 1 mM EDTA in PBS buffer overnight at 4 C.  The degree of oxidation was 6 
estimated via the thiobarbituric acid reactive substances (TBARS) assay and expressed in nmol 7 
malondialdehyde (MDA) equivalent per mg protein.  8 
MALDI-TOF-MS 9 
The MALDI-TOF-MS (AXIMA-Performance; Shimadzu Corporation) equipped with 10 
nitrogen pulsed UV laser (337 nm) was operated using a positive ion source in ‘Reflectron’ 11 
mode and the laser power was set at 90 mV. Each spot was analyzed using a random raster of 12 
200 profiles, and each profile consisted of data from five laser shots. The data were collected 13 
with the Launchpad 2.8 software (Shimadzu Corporation). The m/z values were externally 14 
calibrated using DHB matrix with human bradykinin fragment 1-7 and angiotensin II as peptide 15 
calibration standards (Sigma-Aldrich Japan G.K., Tokyo, Japan). The identification of lipids 16 
prepared from Cu2+-oxLDL was confirmed by MALDI-TOF-MS/MS with reference to product 17 
ion spectra of authentic lipid standards. 18 
Cell culture and intracellular lipid accumulation assay 19 
Intracellular lipid accumulation was studied by using murine macrophage-like cell line, 20 
J774A.1 (Riken Cell Bank, Tsukuba, Japan). The cells were maintained in RPMI-1640 medium 21 
supplemented with 10% FBS. The cells were seeded onto 24-well culture plates at a density of 22 



































































nLDL or copper sulfate-modified oxLDL (Cu2+-oxLDL) for 6 hours. After incubation, the cells 1 
were washed with PBS, collected by centrifugation, and spotted onto the indium tin oxide 2 
(ITO)-coated conductive glass slide (Sigma-Aldrich Japan G.K., Tokyo, Japan). The sample 3 
was then mounted with DHB solution, dried and directly analyzed by MALDI-TOF-MS. 4 
Tissue section preparation 5 
Frozen WHHL rabbit aorta was sectioned at 10m thickness using Cryostat Leica 6 
CM1860 (Leica Microsystems, Solms, Germany). Several serial sections were mounted onto: 7 
(i) The MAS-coated glass slides (Matsunami Glass Industries, Osaka, Japan) for histochemical 8 
staining, and (ii) ITO-coated conductive glass slide for iMScope. Specimens were stored in 9 
slide chamber at kept at -80 °C until use.  10 
Histochemical staining 11 
The frozen serial tissue sections were stained with Oil Red O for visualization of neutral 12 
lipids. The counterstaining of nucleus was performed with the Mayer’s hematoxylin solution 13 
(Wako Pure Chemical Industries, Ltd., Osaka, Japan). Bright field microscopy images of Oil 14 
Red O stained tissue sections were obtained by Keyence BZ-X700 All-in-one Fluorescence 15 
Microscope (Keyence Corporation, Itasca, IL). 16 
Visualization of lipids distributions in aortic lesions by imaging mass microscope (iMScope) 17 
A total of 50 mg/mL of DHB [reconstituted in methanol/1% TFA/distilled water (7:1:2, 18 
v/v)] was used as a matrix. The prepared sample glass slides were spray-coated with 500 L 19 
DHB matrix solutions via a 0.3 mm nozzle caliber airbrush (Procon Boy FWA Platinum; GSI 20 
Creos Co., Tokyo, Japan). Thereafter, the glass slides were vacuum-dried, and followed by 21 
visualization of lipid distributions with iMScope. iMScope was performed using 1,000 Hz solid 22 



































































ionization. The m/z values in the mass range of 350-800 were measured and were internally 1 
calibrated with DHB. All the spectra were acquired using atmospheric pressure MALDI 2 
(Shimadzu Corporation). The spectra were normalized based on total ion current (TIC) to 3 
eliminate variations in ionization efficiency, by using the Imaging MS Solution 1.01.00 4 
software (Shimadzu Corporation). Substances in specified regions were compared by Region 5 
of Interest (ROI) analysis and the differences in areas within ROI were analyzed by the Welch’s 6 
t-test. The identities of lipids were further confirmed by MALDI-MS/MS with reference to 7 
authentic lipid standards. 8 
Statistical analysis 9 
Statistical significance with p-value of less than 0.05 was considered as statistically 10 
significant. The p-value of comparison for region of interest (ROI) analyses was assessed via 11 
average peak intensities or signals acquired from MS spectra of areas indicated by ROI. Low 12 
p-values (p < 0.05) denotes significant differences between average peak intensities or signals 13 
of targets within the stipulated ROIs. 14 
Results 15 
Analysis of oxidized lipids from lipoprotein fractions by MALDI-TOF-MS 16 
Oxidation rate of LDL was evaluated via TBARS assay. A distinct difference in MDA 17 
content between nLDL and oxLDL was observed. nLDL recorded 4 nmol MDA equivalent/mg 18 
protein while oxLDL recorded 220 nmol MDA equivalent/mg protein (Supplementary Fig. 2). 19 
These observations highlighted the oxidation of nLDL into oxLDL. MS profiles of cholesterol 20 
and related oxidized lipid reference standards were first set-up by using authentic standards 21 
(Supplementary Fig. 3). The reference mass profile of different oxidized lipids is shown in 22 



































































m/z 423 [M+Na]+, respectively. As for oxLig-1, it was detected at m/z 593 as a sodium adduct 1 
ion [M+Na]+. 2 
The MS profiles of derived nLDL and Cu2+-oxLDL are shown in Supplementary Fig. 4. 3 
Potential identity of oxidized lipids detected in mice-derived lipoprotein fractions was then 4 
determined with reference to MS profiles of authentic standards. The results showed that the 5 
oxidation products of cholesterol and its ester were detected only in Cu2+-oxLDL. Product ion 6 
peak at m/z 383 [M+H-H2O]
+ was derived from 7-K and oxLig-1; these MS fingerprints were 7 
comparable to the MS profiles of authentic standards. In addition, the presence of “molecule 8 
A” in Ldlr-/- mice derived Cu2+-oxLDL were postulated as oxysterols such as 27-OH, 25-OH 9 
or 7-OH, which were detected at m/z 385 [M+H-H2O]
+ and m/z 367 [M+H-2H2O]
+, 10 
respectively (Supplementary Fig. 4A). 11 
Contrarily, cholesterol and cholesterol linoleate (CE 18:2) were detected in both nLDL 12 
and Cu2+-oxLDL (Supplementary Fig. 4A and B). The product ion of cholesterol was detected 13 
at m/z 369 [M+H-OH]+ while CE 18:2 was detected as protonated precursor ion at m/z 671 14 
[M+Na]+. By comparing the MS spectra of two different lipoprotein fractions, CE 18:2 existed 15 
abundantly in nLDL fraction while its abundance was notably reduced in the oxidized 16 
lipoprotein fraction. Meanwhile two oxCEs of CE 18:2: 9-HODE-CE and oxoODE-CE, were 17 
detected only in Cu2+-oxLDL with the identified protonated precursor ions peaks at m/z 687 18 
and m/z 685 respectively, as [M+Na]+ adduct ion (Supplementary Fig. 4B).  19 
In addition, we have also identified several biological membranous lipids including 20 
SM34:1, phosphatidylcholine (PC) 32:0 (16:0/16:0) and PC 34:2 (16:0:18:2). The presence of 21 
these biological membranous lipids were confirmed in both nLDL and oxLDL lipid fractions 22 
at m/z 703, m/z 734 and m/z 758, respectively (Supplementary Fig. 4C). 23 
From these results, we concluded that the MS profiles of specific molecular ions acquired 24 



































































from sera of the knock-out mice. Contrarily, direct detection of full length oxLig-1 from Cu2+-1 
oxLDL by MALDI-TOF-MS was constrained. Characteristic MS fingerprint of oxLig-1 (at m/z 2 
593) was not detected in both lipid fractions. Hence, an alternative study model involving the 3 
use of murine macrophage-like J774A.1cells was employed to detect the presence of oxLig-1 4 
in Cu2+-oxLDL. 5 
Phagocytosis of oxLDL by murine macrophage-like cell line, J774A.1 6 
Brown AJ et. al. (2000) indicated that both cholesterol and 7-K, along with their esters 7 
were assessable in macrophages loaded with modified lipoproteins [34]. In this study, the 8 
J774A.1 cells were used as an in vitro study model to evaluate the intracellular lipid 9 
accumulation of oxidized lipids. Detection of oxidized lipids from the cells was then performed 10 
by MALDI-TOF-MS (Fig. 1A). The MS spectra of nLDL and Cu2+-oxLDL were obtained from 11 
the macrophage pre-incubated with either nLDL or Cu2+-oxLDL at final concentrations of 20 12 
g/ml for 6 hours. The detected MS profiles of oxidized lipids derived from Cu2+-oxLDL 13 
treated J774A.1 cells (Fig. 1B) were comparable to that derived from Cu2+-oxLDL fraction 14 
(Supplementary Fig. 4). Yet, the obtained spectral signal of oxLig-1 was weak and thus limiting 15 
its identification by MS/MS. 16 
MS imaging of cholesterol oxidation process on atherosclerosis plaque in WHHL Rabbit 17 
The distributions of lipids and their associated oxidized forms in atherosclerotic plaque 18 
were visualized by the novel iMScope with a MS imaging technology. Direct detections of 19 
lipids obtained from atherosclerosis plaque were made possible without the utilization of 20 
antibody or extensive purification steps. Fig. 2 shows the optical microscopic image and MS 21 
visual mappings of lipids and oxidized lipids on two regions of sectioned aortic tissues from 22 



































































The two regions of interest of sectioned aortic tissue (shown in Fig. 2) consisted of 1 
atherosclerotic lesions of different sizes: large (Fig. 2A) and small lesions (Fig. 2B). Both Fig. 2 
2A and B depicted the visual mappings of different lipid targets. The targeted lipids include: 3 
(a) cholesterol; (b) CE 18:2; (c) PCs (PC 32:0, PC 34:2, PC 37:4, PC 36:2); (d) SMs [SM 34:1 4 
(18:1/16:0), SM 33:1 (d18:1/15:0)]; (e) lysoPCs [lysoPC (16:0), lysoPC (18:2), lysoPC (18:0), 5 
lysoPC (18:1), lysoPC (22:0)]; (f) oxidized lipid targets (“molecule A”, 7-K, OxoODE-CE, 6 
HODE-CE). Cholesterol was homogenously distributed over the entire plaque areas of both 7 
small and large lesions. CE 18:2, SMs, PCs, and oxidized lipid targets showed strong 8 
localizations in plaque of large lesion (Fig. 2A) while these signals were weak in small lesion 9 
(Fig. 2B). The localizations of lysoPCs were mostly distributed over the plaque area of small 10 
lesion (Fig. 2B). Though lysoPCs also localized across the plaque area of large lesion, it was 11 
interesting to note that strong localizations were particularly observed near the shoulder region 12 
of large atherosclerotic lesion (Fig. 2A).  13 
To evaluate the relative abundance and distribution of detectable lipids in the sampled 14 
aortic tissues, we further analyzed the mass spectra data through multiple region of interest 15 
(ROI) analyses of detectable lipids (Fig. 3A and 4A). The relative abundance of lipids by their 16 
p-values were compared between randomly selected ROIs in plaque and vessel regions of the 17 
sectioned aortic tissues. The arterial media of the unaffected section of the sampled aorta was 18 
used as a control for comparison. For the large lesion (Fig. 3A), the relative abundance of 19 
targeted oxidized lipids, lysoPCs, SMs, and PCs in plaque and unaffected arterial media were 20 
significantly different. These lipids were largely distributed over the plaque area as opposed to 21 
the unaffected arterial media [Fig. 3A(i) and (ii)]. As for lysoPCs, their strong localizations at 22 
the shoulder region of atherosclerotic plaque [Fig. 3A(i) and (iii)] were distinctive and 23 
significantly different from other ROIs. Similar trends of lipid localizations were also observed 24 



































































34:1 were significantly different from those in unaffected arterial media [Fig. 4A(i) and (ii)].  1 
They were mostly localized in plaque and its shoulder region as opposed to the unaffected 2 
arterial media.  In contrast to the localizations of lysoPC in large lesion, the distributions of 3 
lysoPCs in small lesion were strongly localized in the plaque region [Fig. 4A (ii) and (iii)]. 4 
Identification of bioactive lipids and visualization of its distributions by MS/MS imaging 5 
Sectioned tissue was subjected to Oil Red O staining to identify the localization of neutral 6 
lipids in atherosclerotic plaque (Fig. 5A). The distributions of oxidized lipids such as oxysterols 7 
(“molecule A”) or oxCEs in sectioned atherosclerotic plaque were then visualized by MS/MS 8 
imaging using iMScope (Fig. 5B) and authentic lipid standards were used to create reference 9 
MS/MS profiles (Fig. 5C). Based upon the derived MS/MS profiles, specific m/z of fragment 10 
ions derived from respective precursor ions of targeted oxidized lipids was used to identify and 11 
visualize each target on samples. Specific m/z of fragment ions used for identification of 12 
targeted lipids were as follow: 7-K and oxLig-1 at m/z 175 (precursor ion: m/z 383) [Fig. 5B 13 
(i)]; “molecule A” could be constituted of oxysterols such as 7-OH, 25-OH, or 27-OH at m/z 14 
159 (precursor ion: m/z 367) [Fig. 5B(ii)]; and oxCEs, at m/z 317 and m/z 319 (precursor ion: 15 
m/z 685 and m/z 687) [Fig. 5B(iii) and (iv))]. By overlaying the acquired MS/MS images with 16 
their respective optical microscope image (Fig. 5B), it was discovered that the intensities of 17 
oxCEs were relatively abundant in large atherosclerotic lesion. Though CEs were extensively 18 
converted to oxidized CEs in large atherosclerotic lesion, the relatively scarce signals acquired 19 
from both 7-K and oxLig-1 may signify the ongoing process of cholesterol oxidation. 20 
Discussions 21 
The study of oxidized lipid metabolism is implicated as one of the pivotal elements 22 
underpinning the etiological study of lifestyle-related disease such as atherosclerosis. To date, 23 



































































classification approach endure limitations such as difficult handling of lipid specimens and 1 
dynamic state of lipoprotein metabolism. In order to tackle these limitations, our present study 2 
employed the use of novel iMScope system with MS/MS imaging technology to identify the 3 
presence of specific oxidized lipids in specimens of atherosclerosis study models.  4 
MALDI-Imaging Mass Spectrometry (MALDI-IMS) was previously used by Hutchins et 5 
al. (2011) to detect CE and oxCE in human vascular lesion. The detected oxCEs were largely 6 
localized within the lesion [35]. In this study, we first used the MALDI-TOF-MS to screen 7 
several lipid targets in Ldlr-/- mice-derived nLDL and Cu2+-oxLDL. We observed that CE 18:2 8 
was only detected in nLDL but not in Cu2+-oxLDL. Contrarily, oxCEs such as 9-HODE-CE 9 
and oxoODE-CE were mostly observed in Cu2+-oxLDL only. These observations suggested 10 
that extensive oxidation-dependent decrement of CEs is associated with the increment of 11 
oxCEs. In addition, Cu2+-modified lipid is known to have undergone extensive oxidation, 12 
hence it is worth to note that dissimilar MS profiles of presumably oxidized lipids from that of 13 
Cu2+-oxLDL may signify incomplete or progressive lipid oxidation. 14 
We subsequently used the 2-dimensional iMScope technology to visualize the distribution 15 
profiles of different lipid targets in sectioned WHHL rabbit’s aortic tissues of two different 16 
sizes (small and large). CE 18:2, PCs, SMs, and the targeted oxidized lipids (“molecule A”, 7-17 
K, OxoODE-CE, HODE-CE) were strongly localized in plaque region of the sampled large 18 
atherosclerotic lesion. It was postulated that the relative abundances of these lipids were 19 
proportional to the sizes of the plaques. Aside from cholesterol and lysoPCs, low relative 20 
abundances of PCs, SMs, and oxidized lipids were observed in small atherosclerotic lesion. As 21 
the development of atherosclerotic plaque progresses gradually, these observations suggested 22 
that the processes of lipid oxidations were still in progress.  23 
Interestingly, we observed unique distribution profiles of lysoPCs in the both small and 24 



































































were largely concentrated at the shoulder region of the plaque as opposed to the uniform 1 
distribution profiles in the small atherosclerotic plaque. It is postulated that the emergences of 2 
lysoPCs in atherosclerotic plaque may represent the onset of neo-atherosclerosis. Endothelial 3 
dysfunction is a clinical manifestation of early atherogenesis.  Several reports have highlighted 4 
that the involvement of PLA2 may contribute to inflammation and endothelial dysfunction in 5 
early atherogenesis through production of lysoPC [36, 37]. Localized PLA2 in human 6 
atherosclerotic plaques have been shown to facilitate the production of oxidized fatty acid and 7 
lysoPC through hydrolysis of sn-2 fatty acids of oxidized phospholipids [38]. LysoPC acts as 8 
a pro-inflammatory mediator of oxidative stress and endothelial dysfunction [39]. It impedes 9 
endothelium-dependent vasodilation through downregulation of endothelial nitric oxide 10 
synthase (eNOS) mRNA expression [39] and halts the migration of endothelial cells and 11 
restoration of arterial injury [40]. 12 
We inferred that the acquisition of strong signals of lysoPCs at the shoulder region of large 13 
atherosclerotic lesion was attributed to the active enzymatic hydrolysis of PCs to lysoPCs in 14 
the region. Lipoprotein-associated phospholipase A2 (PLA2) is consistently generated by 15 
macrophage under oxidative stress [38]. As the phosphatide composition of LDL bio-16 
membrane mainly consist of PC, PLA2 hydrolyzes PC to hydroperoxide (PC-OOH), then to 17 
lysoPC and free fatty acid hydroperoxide (FFA-OOH) [41]; by hydrolyzing the sn-2 fatty acids 18 
of phospholipids and complements the formation of lysoPC and eventually to CE in later stages 19 
[42, 43]. 20 
Notably, we managed to detect and identify faint signals of 7-K, in its ionized form, from 21 
atherosclerosis plaque by MS/MS imaging. Though 7-K was the second most abundant 22 
oxysterols found in human atherosclerotic plaque after 27-OH [5], we were unable to identify 23 
the full length or other ionized form of both 7-K and oxLig-1. We speculated that the 24 



































































progresses gradually, such observation suggested that lipid oxidations were still in progress. In 1 
human, the development of atherosclerosis began at early age and it progresses over decades 2 
before it eventually reaches the vascular occlusion/rupture stage [44]. Since the detection of 3 
both 7-K and oxLig-1 by iMScope play a key part in the accomplishment of our present study, 4 
our observations suggest that an extended timepoint study using similar animal model (more 5 
than 6 months) is deemed necessary to comprehensively assess the distributions of 7-K and 6 
oxLig-1 in plaques. 7 
On the contrary, there were also alternative inferences which may support our present 8 
findings. In human, 7-K accumulates specifically in fatty streak lesion [7]. The relatively low 9 
concentration of 7-K in atherosclerotic lesions of WHHL rabbit as reported in this study than 10 
that of human atherosclerotic plaques could be a probable inference to support the acquisition 11 
of low signal of 7-K by iMScope. In addition, it was also inferred that macrophages can initiate 12 
homeostatic regulatory mechanism to compensate cholesterol influx by promoting ATP 13 
binding cassette transporters A1 and G1 (ABCA1 and ABCG1) mediated cholesterol efflux 14 
pathways [45]. However, such compensatory mechanism is limited to non-15 
hypercholesterolemia condition only [46].  Nonetheless, such postulation could be less 16 
important in rabbit as 27-OH, formed from cholesterol by sterol 27-hydroxylase (CYP27A1), 17 
is the most abundant oxysterol in atherosclerotic plaques [47-49]. To put all things into 18 
perspective, there is a possibility that large amount of 7-K and oxLig-1 may not be detected in 19 
atherosclerotic plaque of rabbit even if the study was performed over a longer period. 20 
It is also worth to note that present study primarily focused on preliminary establishment 21 
and application of iMScope with MS/MS imaging technology to visualize the distributions of 22 
targeted lipids in atherosclerotic plaques. A few limitations remain to be address before such 23 
combinational technology can be put into feasible use. First of all, our data showed that the 24 



































































to the complexity of biological tissue, various co-existing biomolecules in the tissue section 1 
tend to influence the crystallization efficiency of biomolecules with the chemical matrix [50]. 2 
Such situation can negatively affect the ionization and desorption efficiency of targeted 3 
biomolecules which subsequently influence the detectable signals and profiles of mass spectra 4 
[51]; a phenomenon known as ion suppression [52]. In addition, repeated laser irradiation at 5 
similar spots during iMScope analysis often lead to loss of ion signals or ion yields. Additional 6 
instrumental optimizations in areas of laser irradiation parameters and effects of different 7 
matrices on yields of MS ion signals remain warranted to further improve the efficiency of 8 
instrumental signal acquisitions. Secondly, lipid oxidation is an ongoing process which may 9 
influence the spatial organization and integrity of lipids in biological tissues. However, in order 10 
to preserve the integrity of the biological tissue and prevent the generation of artifacts from 11 
oxidation of lipids as a result of improper sample handling, we preserved the collected aortic 12 
tissue immediately in O.C.T. compound and stored at −80°C. Thirdly, current iMScope with 13 
MS/MS imaging application focused on only one WHHL rabbit’s aortic tissue that was 14 
randomly selected for analysis as a proof of concept. The technology still needs to be tested 15 
with more diverse tissue specimens, comprises of mildly and severely developed 16 
atherosclerotic plaques from pathological study model (e.g. WHHL rabbits) and non-17 
pathological normal control models [e.g. Japanese White (JW-NIBS) strain rabbit - genetic 18 
background of WHHL rabbit] to further complement its sensitivity and specificity. Such future 19 
study will provide valuable insights especially on lipidomics and pathophysiological 20 
development of atherosclerosis.  21 
The application of iMScope with MS/MS imaging technology offers an interesting 22 
proposition to study the pathophysiology of atherosclerotic plaque formation from the context 23 
of oxidized lipids. Based on our present findings, we were able to detect and visualize the 24 



































































findings further support the applicability of iMScope as a direct approach for detection of lipid 1 
peroxides from fresh/frozen sections of tissue samples. It abolished the need for pre-analysis 2 
sample extraction, thus preserving the integrity of the specimen while keeping its susceptibility 3 
to oxidation at minimal level. At present, it is anticipated that such attempt can shed lights on 4 
identities of crucial oxidized lipids that are responsible for development and progression of 5 
atherosclerotic lesions. 6 
Conclusions 7 
iMScope with MS/MS imaging was successfully applied as a direct approach to analyze 8 
and visualize the distribution of targeted oxidized lipids in atherosclerotic lesions derived from 9 
atherosclerotic study models.  The combination of imaging and MS/MS technology offers a 10 
valuable proposition that enables one to visualize the distributions of different lipid targets in 11 
plaques at different developmental stages. 12 
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Figure Legends 1 
Fig. 1: Uptake of oxLDL by murine macrophage-like J774A.1 cells.  2 
(A) In vitro intracellular lipid accumulation was studied by using the J774A.1 cells. The 3 
cells were pre-incubated with 20 g/ml nLDL or oxLDL for 6 hours, and were 4 
subsequently analyzed by MALDI-TOF-MS. (B) The MS profiles of macrophage 5 
loaded with either nLDL or oxLDL showed product ion peaks at specific m/z 6 
corresponded to different lipid targets: m/z 369  cholesterol ion [M+H-OH], m/z 383 7 
 7-K [M-OH]-, m/z 401  7-K [M+H]+, and m/z 367 [M+H-2H2O]
-& m/z 385 [M+H-8 
H2O]  “molecule A” (potentially constituted of 7-OH, 25-OH or 27-OH). 9 
Fig. 2: MS imaging-based visual mapping profiles of oxidized lipid distributed within regions 10 
of randomly sampled atherosclerotic lesion.  11 
Distinctive lipid profiles were observed in two different regions of sampled 12 
atherosclerotic lesion. The presented data were representatives of two regions of 13 
sectioned atherosclerotic lesion: (A) large lesion and (B) small lesion selected for 14 
analyses. A total of 6 different regions of large lesion (Supplementary Fig. 5) and 2 15 
different regions of small lesion (Supplementary Fig. 6) were analyzed.  The targeted 16 
lipids include: cholesterol;  CE 18:2; PCs (PC 32:0, PC 34:2, PC 37:4, PC 36:2); SMs 17 
[SM 34:1 (18:1/16:0), SM 33:1 (d18:1/15:0)]; lysoPCs [lysoPC (16:0), lysoPC (18:2), 18 
lysoPC (18:0), lysoPC (18:1), lysoPC (22:0)]; and oxidized lipid targets (“molecule 19 
A”, 7-K, OxoODE-CE, HODE-CE).  20 
Fig. 3: Distribution profiles of lipids in large atherosclerotic lesion were studied through 21 
comparisons of relative intensities of lipids by p-values between ROI-1 and ROI-2 (A) 22 



































































analyses. Signal intensities of targeted lipids in ROI of two different regions of sampled 1 
lesion were depicted respectively and signal normalization was performed by pixel. A 2 
total of three different sets of comparisons were made: A(i) ROI-1 shoulder of 3 
atherosclerotic plaque versus ROI-2 unaffected arterial media; A(ii) ROI-1 plaque 4 
versus ROI-2 unaffected arterial media; A(iii) ROI-1 plaque region 1 versus ROI-2 5 
plaque region 2.  The letter ‘p’ denotes the statistical p-value of the comparison, 6 
significant differences are highlighted in green font while insignificant differences are 7 
highlighted in red font. (B) Total ion chromatograms (TIC) of MS analysis on ROI of 8 
each region of sectioned lesion. ROI for unaffected arterial media was selected from 9 
preliminary evaluations (Supplementary Fig. 7) on multiple regions of arterial media 10 
with low MS signals of cholesterol as compared to the plaque region. 11 
Fig. 4: Distribution profiles of lipids in small atherosclerotic lesion were studied through 12 
comparisons of relative intensities of lipids by p-values between ROI-1 and ROI-2 (A) 13 
(n = 3). The ‘n’ in this context denotes the number of serial tissue sections used for 14 
analyses. Signal intensities of targeted lipids in ROI of two different regions of sampled 15 
lesion were depicted respectively and signal normalization was performed by pixel. A 16 
total of three different sets of comparisons were made: A(i) ROI-1 shoulder of 17 
atherosclerotic plaque versus ROI-2 unaffected arterial media; A(ii) ROI-1 plaque 18 
versus ROI-2 unaffected arterial media; A(iii) ROI-1 plaque region 1 versus ROI-2 19 
plaque region 2.  The letter ‘p’ denotes the statistical p-value of the comparison, 20 
significant differences are highlighted in green font while insignificant differences are 21 
highlighted in red font. (B) Total ion chromatograms (TIC) of MS analysis on ROI of 22 
each region of sectioned lesion. ROI for unaffected arterial media was selected from 23 
preliminary evaluations (Supplementary Fig. 8) on multiple regions of arterial media 24 



































































Fig. 5: MS/MS imaging visual mapping of oxysterol and oxCEs detected on sampled WHHL 1 
rabbit atheroma.  2 
Sectioned atherosclerotic lesion of WHHL rabbit was assessed through (A) Oil Red O 3 
staining for distribution of neutral lipids and (B) MS/MS imaging for distribution of 4 
oxidized lipids. MS/MS imaging visual mapping of targeted oxidized lipids (in green) 5 
were overlaid onto the optical microscopy image of sampled lesion (n = 3). MS/MS 6 
imaging visual mappings of targeted oxidized lipids of all sampled lesions were 7 
depicted in Supplementary Fig. 9. MS profiles of targeted oxidized lipids detected in 8 
specific regions of large atherosclerotic lesion of WHHL rabbit and their corresponding 9 
reference standards were depicted in Supplementary Fig. 3. (C)  MS/MS profiles of 10 
targeted oxidized lipids detected in specific regions of large atherosclerotic lesion of 11 
the WHHL rabbits and the corresponding MS/MS profiles of reference standards of 12 
targeted oxidized lipids. “Molecule A” was postulated consisting of oxysterols such as 13 
7-OH, 25-OH or 27-OH. Collision energies and corresponding MS/MS fragment ions 14 
of targeted oxidized lipids were presented in Table S1.  15 
 16 
Supplementary Fig. 1: Cholesterol oxidation pathway. Oxidation of cholesterol can occur 17 
enzymatically and non-enzymatically. Enzymatic oxidation of cholesterol mostly yields 18 
esterified lipid moieties while non-enzymatic oxidation of cholesterol produces 19 
oxysterols such as 7-hydroperoxycholesterol (7-OOH) and 7-ketocholesterol (7K). 20 
Enzymatic oxidation of 7-K further yields 7-ketocholesterol ester (7-KE) and 21 
subsequent oxidation of 7-KE yields 7-ketocholesteryl-9-carboxynonanoate (oxLig-1), 22 
a major ligand for β2GPI. The reduction of 7-K to 7-OOH is catalyzed by 11β-HSD1 23 
enzyme [53]. Red arrow denotes the fragmentation sites of lipids. CYP27: sterol 27-24 



































































hydroxysteroid-dehydrogenase type I/ type II; LCAT: lecithin cholesterol 1 
acyltransferase; ACAT: acyl-CoA:cholesterol acyltransferase. 2 
Supplementary Fig. 2: Oxidation of LDL was evaluated through TBARS assay. The extent 3 
of lipid oxidation was expressed in nmol MDA equivalent per mg protein. 4 
Supplementary Fig. 3: MS spectra of authentic lipid standards. Authentic lipid standards: (a) 5 
cholesterol; (B) 27-hydroxycholesterol (27-OH); (C) 25-hydroxycholesterol (25-OH); 6 
(D) 7-hydroxycholesterol (7-OH); (E) 7-ketocholesterol (7-K); (F) 7-ketocholesteryl-7 
9-carboxynonanoate (oxLig-1; synthesized in-house); (G) cholestryl linoleate (CE 8 
18:2); (H) 9-hydroxy-10E,12Z-octadecadienoic acid cholestryl ester (9-HODE-CE) 9 
were analyzed by MALDI-TOF-MS and the acquired signals were represented in a plot 10 
of mass/charge ratio (m/z, X-axis) against their relative abundance (Y-axis). 11 
Supplementary Fig. 4: MS profiles of lipids from nLDL and oxLDL. MS profiles of nLDL 12 
and oxLDL derived from Ldlr-/- mice were acquired by using MALDI-TOF-MS. The 13 
m/z values in the range of m/z 350-800 were measured and the zoomed-in MS profiles 14 
in the range of (A) m/z 365-405, (B) m/z 668-695, and (C) m/z 696-766 were depicted 15 
accordingly. 16 
Supplementary Fig. 5: MS imaging-based visual mapping profiles of oxidized lipid 17 
distributed within regions of randomly sampled atherosclerotic lesion. A total 6 18 
different regions of large lesion (A-F) were analyzed. The targeted lipids include: 19 
cholesterol; lysoPCs [lysoPC (16:0), lysoPC (18:0), lysoPC (18:2), lysoPC (18:1), 20 
lysoPC (22:0)]; SM 34:1 (18:1/16:0); and PCs [PC 32:0 (16:0/16:0), PC 37:4 21 
(22:4/15:0)]. 22 
Supplementary Fig. 6: MS imaging-based visual mapping profiles of oxidized lipid 23 



































































different regions of small lesion (A & B) were analyzed. The targeted lipids include: 1 
cholesterol; lysoPCs [lysoPC (16:0), lysoPC (18:0), lysoPC (18:2), lysoPC (18:1)]; 2 
SM 34:1 (18:1/16:0); and PCs [PC 32:0 (16:0/16:0), PC 37:4 (22:4/15:0)]. 3 
Supplementary Fig. 7: Preliminary evaluations of ROI for unaffected arterial media near 4 
region of large lesion. Multiple ROI (6 different regions) of unaffected arterial media 5 
were selected to evaluate the presence of cholesterol. ROI of unaffected arterial media 6 
was selected based on none/low MS signals of cholesterol (m/z 369.35) (as compared 7 
to the plaque region). MS signals of cholesterol (m/z 369.35) were annotated with red 8 
triangle. 9 
Supplementary Fig. 8: Preliminary evaluations of ROI for unaffected arterial media near 10 
region of small lesion. Multiple ROI (6 different regions) of unaffected arterial media 11 
were selected to evaluate the presence of cholesterol. ROI of unaffected arterial media 12 
was selected based on none/low MS signals of cholesterol (m/z 369.35) (as compared 13 
to the plaque region). MS signals of cholesterol (m/z 369.35) were annotated with red 14 
triangle. 15 
Supplementary Fig. 9: MS/MS imaging for distribution of oxidized lipids. MS/MS imaging 16 
visual mapping of targeted oxidized lipids were overlaid onto the optical microscopy 17 
image of sampled lesions (n = 3). MS profiles of targeted oxidized lipids detected in 18 
specific regions of large atherosclerotic lesion of WHHL rabbit and their corresponding 19 
reference standards were depicted in Supplementary Fig. 3. The insets depict the 20 
MS/MS profiles of targeted oxidized lipids detected in specific regions of large 21 
atherosclerotic lesion of the WHHL rabbits and the corresponding MS/MS profiles of 22 
reference standards of targeted oxidized lipids. “Molecule A” was postulated consisting 23 






































































































































 We assembled a panel of oxidized lipids relating to progression of atherosclerosis 
 iMScope can visualize distribution of lipid peroxides within atherosclerotic plaque 
 MALDI-TOF-MS is able to characterize bioactive lipids from sectioned tissue 
samples 
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